Biological Retention Rates, the Reasons of Switching, and Prognostic Factors in Patients with Psoriasis Treated Biologics.

Tokuyama, Michio; Ota, Mizuho; Saitoh, Reiko; Sawamura, Miho; Okitsu, Narumi; Shimizu, Tomomichi; Kondoh, Akio; Yamaoka, Hanako; Mabuchi, Tomotaka

Tokuyama, Michio; Ota, Mizuho; Saitoh, Reiko; Sawamura, Miho; Okitsu, Narumi; Shimizu, Tomomichi; Kondoh, Akio; Yamaoka, Hanako; Mabuchi, Tomotaka.

Affiliation

Tokuyama M; Department of Dermatology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. tokuyama@tokai-u.jp.

Tokai J Exp Clin Med ; 45(4): 230-235, 2020 Dec 20.

Article in En | MEDLINE | ID: mdl-33300595

Subject(s)

Adalimumab/therapeutic use; Biological Factors/therapeutic use; Clinical Reasoning; Drug Substitution; Infliximab/therapeutic use; Psoriasis/drug therapy; Ustekinumab/therapeutic use; Adalimumab/adverse effects; Adalimumab/economics; Adult; Arthritis, Psoriatic/drug therapy; Biological Factors/adverse effects; Biological Factors/economics; Female; Humans; Infliximab/adverse effects; Infliximab/economics; Male; Middle Aged; Nail Diseases/etiology; Prognosis; Pruritus/etiology; Retrospective Studies; Treatment Outcome; Ustekinumab/adverse effects; Ustekinumab/economics

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Biological Factors / Drug Substitution / Adalimumab / Ustekinumab / Infliximab / Clinical Reasoning Type of study: Etiology_studies / Observational_studies / Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Tokai J Exp Clin Med Year: 2020 Document type: Article Affiliation country: Japan Country of publication: Japan

Search on Google

Add to My VHL

XML

PubMed Links